Be alerted to new data & content
Be the first to see:
✔ The latest product updates
✔ Receive relevant supportive materials and resources
KEYTRUDA in Stage IIB/C melanoma
KEYTRUDA® (PEMBROLIZUMAB) IN RESECTED STAGE IIB AND IIC MELANOMA
Moving from observation to action
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA as monotherapy is indicated for:
- The treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma
- The adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection
Did you know that patients with resected Stage IIB and IIC melanoma are still at high risk of recurrence?
Relapse rates in patients with Stage IIB melanoma are 32%, increasing to 46% in Stage IIC melanoma
Recent data from a US-based study shows recurrence rates in patients with Stage IIB–IIC melanoma range from 32–46%; of these, 30–52% recur with distant metastasis.1
Stage IIB and Stage IIC relapse rates1
Node Negative (MO)
After surgical resection of Stage IIB and IIC melanoma, patients are still at high risk of recurrence, with
half of relapses occurring within 2 years.
Stage IIB and Stage IIC median time to relapse1
Stage IIB and Stage IIC patients who relapsed with distant metastasis1
Percentage of patients who relapsed with distant metastasis as first relapse*
GI = Gastrointestinal
*The remainder of patients experienced a local/in-transit or regional nodal relapse.
A retrospective review of 738 adult patients from a prospectively maintained, single-institution database, with resected pathologic Stage II primary cutaneous melanoma (AJCC 7th ed.). All patients were treated at Memorial Sloan Kettering Cancer Center, USA, between January 1993 and December 2013. Patients underwent pathological nodal staging by sentinel lymph node biopsy or elective lymph node dissection. Median follow-up of patients with Stage IIB and Stage IIC melanoma was 4.3 years (50.2 and 46.2 months, respectively). Synchronous initial relapses were scored by the most advanced site. Secondary primary melanomas were not recorded as relapses.
Melanoma-specific survival rates at 5 and 10 years based on AJCC 8th edition pathologic melanoma staging criteria2
Survival data generated using IMDPP database, containing records of >46,000 patients with melanoma (n=43,792 qualified for analysis). Included patient records from 10 institutions in the US, Europe and Australia with melanoma at Stage I–III at initial diagnosis and had received treatment since 1998.
Take the quiz
How can KEYTRUDA support your eligible patients with Stage IIB and IIC melanoma?
KEYTRUDA is now available as an adjuvant treatment option for
your eligible Stage IIB and IIC resected melanoma patients.3
Interim Analysis 1
The marketing authorisation was gained based on data from KEYNOTE-716, which was a multicentre, randomised, double-blind, placebo-controlled phase III trial in patients with completely resected Stage IIB or IIC melanoma. 976 patients were randomised to receive either KEYTRUDA (n = 487) Q3W or placebo (n = 489) Q3W for up to 1 year.4
If you want to learn more about KEYTRUDA in the adjuvant treatment of Stage IIB/C melanoma, download our clinical data presentation
Primary endpoint: Kaplan-Meier estimates of recurrence-free survival in the ITT population at the first interim analysis*†4
Adapted from: Luke JJ et al. Lancet 2022;399:1718–1729
*RFS was defined as the time from randomisation to the date of first recurrence of melanoma at any site (local, in-transit or regional lymph nodes, or distant recurrence) or death due to any cause, whichever occurred first.
†Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by melanoma T category (T3b vs. T4a vs. T4b). IA1 data cutoff: 04 December 2020.
In the first interim analysis, at a median follow up of 14.4 months, a HR of 0.65 demonstrated a 35% relative risk reduction in disease recurrence with KEYTRUDA vs. placebo.4
The safety profile of KEYTRUDA among the patients with resected melanoma enrolled in KEYNOTE‑716 was consistent with previous studies.4
Treatment-related adverse events at the first interim analysis*
| KEYTRUDA (n = 483) | KEYTRUDA (n = 483) | Placebo (n = 486) | Placebo (n = 486) | |
|---|---|---|---|---|
| Any | Grade ≥3 | Any | Grade ≥3 | |
| Any cause adverse event | 449 (93%) | 125 (26%) | 433 (89%) | 83 (17%) |
| Any treatment-related adverse event | 386 (80%) | 78 (16%) | 296 (61%) | 21 (4%) |
| Treatment-related events occurring in ≥5% of patients in each group | ||||
| Hypothyroidism | 70 (14%) | 0 | 12 (2%) | 0 |
| Hyperthyroidism | 48 (10%) | 1 (<1%) | 3 (1%) | 0 |
| Diarrhoea | 85 (18%) | 5 (1%) | 51 (10%) | 1 (<1%) |
| Nausea | 38 (8%) | 0 | 31 (6%) | 0 |
| Fatigue | 98 (20%) | 1 (<1%) | 87 (18%) | 0 |
| Asthenia | 43 (9%) | 1 (<1%) | 40 (8%) | 0 |
| Arthralgia | 69 (14%) | 1 (<1%) | 35 (7%) | 0 |
| Myalgia | 27 (6%) | 2 (<1%) | 14 (3%) | 0 |
| Increased alanine aminotransferase | 34 (7%) | 4 (1%) | 18 (4%) | 1 (<1%) |
| Increased aspartate aminotransferase | 28 (6%) | 1 (<1%) | 8 (2%) | 1 (<1%) |
| Pruritus | 112 (23%) | 3 (1%) | 48 (10%) | 0 |
| Rash | 75 (16%) | 7 (1%) | 29 (6%) | 1 (<1%) |
| Hypothyroidism | 76 (16%) | 0 | 17 (3%) | 0 |
| Hyperthyroidism | 50 (10%) | 1 (<1%) | 3 (1%) | 0 |
| Colitis | 17 (4%) | 8 (2%) | 4 (1%) | 0 |
| Adrenal insufficiency | 11 (2%) | 4 (1%) | 0 | 0 |
| Hepatitis | 10 (2%) | 8 (2%) | 3 (1%) | 2 (<1%) |
| Hypophysitis | 10 (2%) | 3 (1%) | 0 | 0 |
| Infusion reactions | 5 (1%) | 0 | 6 (1%) | 0 |
| Myasthenic syndrome | 2 (<1%) | 2 (<1%) | 0 | 0 |
| Myelitis | 1 (<1%) | 1 (<1%) | 0 | 0 |
| Myocarditis | 0 | 0 | 1 (<1%) | 1 (<1%) |
| Myositis | 6 (1%) | 3 (1%) | 0 | 0 |
| Nephritis | 7 (1%) | 2 (<1%) | 0 | 0 |
| Pancreatitis | 2 (<1%) | 2 (<1%) | 0 | 0 |
| Pneumonitis | 9 (2%) | 1 (<1%) | 3 (1%) | 0 |
| Sarcoidosis | 5 (1%) | 0 | 0 | 0 |
| Severe skin reactions | 14 (3%) | 13 (3%) | 3 (1%) | 3 (1%) |
| Thyroiditis | 8 (2%) | 0 | 2 (<1%) | 0 |
| Type 1 diabetes | 2 (<1%) | 2 (<1%) | 0 | 0 |
| Uveitis | 1 (<1%) | 0 | 0 | 0 |
Adapted from: Luke JJ et al. Lancet 2022;399:1718-1729.
Summary of adverse events in KEYNOTE-716 at first interim analysis*
| AEs, n (%) | KEYTRUDA (n = 483) | Placebo (n = 486) |
|---|---|---|
| Any | 449 (93) | 433 (89) |
| Grade 3–5 | 125 (26) | 83 (17) |
| Treatment-related | 386 (80) | 296 (61) |
| Grade 3–5 | 78 (16) | 21 (4) |
| Led to discontinuation | 75 (16) | 20 (4) |
| Led to death | 0 | 4 (0.8)† |
Adapted from: Luke JJ et al. Lancet 2022;399:1718–1729
*The safety population included all patients who were randomly assigned to treatment and received at least one dose of study treatment.
†Four deaths occurred: one due to COVID-19-related pneumonia, one due to pneumonia, one due to recurrent cancer, and one due to suicide.
KEYTRUDA is associated with immune-related adverse events. Please refer to the Summary of Product Characteristics for full details about adverse events and their management.3
Interim Analysis 3
Secondary endpoint: Kaplan-Meier estimates of distant metastasis-free survival* in the ITT population at the third interim analysis†7
Adapted from: Long GV et al. Lancet Oncol 2022;23(11):1378–1388
IA3 data cutoff: January 04, 2022.
*DMFS was defined as the time from randomisation to the first diagnosis of distant metastasis.
†Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by melanoma T category (T3b vs. T4a vs. T4b).
In the third interim analysis, at a median follow up of 27.4 months, a HR of 0.64 demonstrated a significant improvement in DMFS with KEYTRUDA vs. placebo.7
The safety profile of KEYTRUDA among patients with resected melanoma in the third interim analysis was similar to the initial analysis.7
Final Analysis
Primary endpoint: Kaplan-Meier estimates of recurrence-free survival* in the ITT population at the final analysis†5
These results are from an exploratory long-term analysis and should be interpreted with caution. Significance was not tested; therefore, no statistical conclusions can be drawn from this analysis
Adapted from: Luke JJ et al. ASCO 2023. Oral presentation
Final analysis data cutoff: January 04, 2023.
*RFS was defined as the time from randomisation to the date of first recurrence of melanoma at any site (local, in-transit or regional lymph nodes, or distant recurrence) or death due to any cause, whichever occurred first.
†Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by melanoma T category (T3b vs. T4a vs. T4b).
In the final analysis, at a median follow up of 39.4 months, adjuvant KEYTRUDA continued to demonstrate a relative risk reduction in disease recurrence vs. placebo.5,6
Secondary endpoint: Kaplan-Meier estimates of distant metastasis-free survival in the ITT population at the final analysis*5
These results are from an exploratory long-term analysis and should be interpreted with caution. Significance was not tested; therefore, no statistical conclusions can be drawn from this analysis
Adapted from: Luke JJ et al. ASCO 2023. Oral presentation
Final analysis data cutoff: 04 January 2023.
*Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by melanoma T category (T3b vs. T4a vs. T4b).
In the final analysis, at a median follow up of 39.4 months, adjuvant KEYTRUDA demonstrated a continued improvement in DMFS vs. placebo.5,6
The safety profile of KEYTRUDA among the patients with resected melanoma in the final analysis of KEYNOTE-716 was consistent with previous analyses.4,7
References
- Lee AY, et al. Ann Surg Oncol. 2017;24(4):939–946.
- Gershenwald JE, et al. CA Cancer J Clin. 2017;67(6):472–492.
- KEYTRUDA Summary of Product Characteristics.
- Luke JJ, et al. Lancet 2022;399:1718–1729.
- Luke JJ, et al. Presented at ASCO 2023, June 2–6, 2023. Oral Presentation.
- Luke JJ, et al. Presented at ASCO 2023. June 2–6, 2023. Abstract LBA9505.
- Long GV et al. Lancet Oncol 2022;23(11):1378–1388.
Abbreviations
AE = Adverse Event; CI = Confidence Interval; DMFS = Distant Metastasis-Free Survival; HR = Hazard Ratio; ITT = Intention-To-Treat; RFS = Recurrence-Free Survival.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
